Valuation: BioLife Solutions, Inc.

Market Cap 1.89B 1.66B 1.56B 1.43B 2.67B 181B 2.69B 18.77B 7.28B 92.18B 7.08B 6.93B 300B P/E 2026 *
36.7x
P/E 2027 * 104x
Enterprise Value 1.89B 1.66B 1.56B 1.43B 2.67B 181B 2.69B 18.77B 7.28B 92.18B 7.08B 6.93B 300B EV / Sales 2026 *
16.4x
EV / Sales 2027 * 14x
Free-Float
97.38%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 2023-10-18
Chief Tech/Sci/R&D Officer 54 2011-01-31
Director of Finance/CFO 41 2021-11-03
Director TitleAgeSince
Chairman 65 2023-10-18
Director/Board Member 52 2021-04-05
Director/Board Member 56 2021-04-05
Change 5-day change 1-year change 3-year change Capi.($)
+0.31%-1.25%-23.99%+3.96% 175B
+1.13%-3.74%-5.96%+10.89% 113B
-1.43%-1.17%+2.12%+63.00% 59.13B
+1.74%+0.71%+0.91%-31.69% 48.82B
+1.49%+3.66%+12.10%+51.47% 48.69B
-0.29%-2.36%+27.74%+1.38% 33.01B
+1.43%+9.96% - - 30.41B
-0.88%+2.06%+45.30%-1.55% 26.29B
-1.58%+7.22%+21.72%-6.35% 23.87B
Average +0.22%+1.64%+9.99%+11.39% 62.04B
Weighted average by Cap. +0.42%-0.27%-2.82%+12.24%

Financials

2026 *2027 *
Net sales 115M 101M 95.55M 87.17M 163M 11.06B 164M 1.15B 444M 5.63B 433M 423M 18.32B 135M 119M 112M 102M 191M 12.94B 192M 1.34B 520M 6.59B 506M 495M 21.44B
Net income 51.92M 45.67M 43.05M 39.28M 73.46M 4.98B 74.03M 517M 200M 2.54B 195M 191M 8.25B 16.82M 14.8M 13.95M 12.73M 23.8M 1.62B 23.99M 167M 64.87M 822M 63.17M 61.8M 2.67B
Net Debt - -
Logo BioLife Solutions, Inc.
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-